Why the study?
Does aggressive neoadjuvant chemotherapy improve long-term disease-free survival in patients with nonmetastatic osteosarcoma of the extremity?
Population
164 patients with nonmetastatic osteosarcoma of the extremity treated at a single institution
Design
Cohort
Follow-up
median 11.5 years (range 10 to 13 years)
Authors
Loading...
Supports durable control with neoadjuvant chemotherapy in extremity osteosarcoma; leaves open optimal regimens and cardiotoxicity surveillance.
Does aggressive neoadjuvant chemotherapy improve long-term disease-free survival in patients with nonmetastatic osteosarcoma of the extremity?
Aggressive neoadjuvant chemotherapy for nonmetastatic extremity osteosarcoma achieves >60% long-term cure rates and >80% limb salvage, though late complications like doxorubicin-induced cardiotoxicity necessitate long-term follow-up.
Bacci et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: